Skip to main content

Table 1 Demographic and clinical characteristics of all study subjects who underwent the first prostate biopsy

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

 

Total

No cancer

Cancer

P value

 

N, 140

 N, 77 (55%)

N, 63 (45%)

Age, yr

69.0 (10.0)

67.0 (9.0)

72.0 (10.0)

0.001

tPSA, ng/mL

6.93 (6.05)

6.45 (3.8)

8.18 (15.3)

0.010

fPSA

1.03 (0.92)

0.92 (0.8)

1.07 (1.4)

0.160

%fPSA

14.55 (9.29)

17.13 (8.0)

11.16 (9.0)

0.003

p2PSA, pg/mL

19.18 (30.97)

15.54 (16.7)

31.06 (58.6)

< 0.001

%p2PSA

2.02 (2.21)

1.57 (1.5)

2.83 (2.6)

< 0.001

PHI

45.90 (82.72)

39.54 (38.0)

91.18 (147.9)

< 0.001

Positive core number

5.0 (7.0)

Number (percentage)

GS 6%

15 (23.8%)

GS 7

  

18 (28.6%)

GS ≥ 8

  

30 (47.6%)

  1. Data are shown as median (interquartile range), or number (%)
  2. PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; p2PSA, [2]proPSA, PHI, prostate health index; GS, Gleason score
  3. P value to be statiscally significant with bolditalics